Skip to main content
main-content
Erschienen in: Annals of Surgical Oncology 7/2019

29.04.2019 | Pancreatic Tumors

A Single-Institution Validation Study of Lymph Node Staging By the AJCC 8th Edition for Patients with Pancreatic Head Cancer: A Proposal to Subdivide the N2 Category

verfasst von: MD Daisuke Asano, MD Satoshi Nara, MD Yoji Kishi, MD Minoru Esaki, MD Nobuyoshi Hiraoka, MD Minoru Tanabe, MD Kazuaki Shimada

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

According to the revised staging of the American Joint Committee on Cancer, 8th edition (AJCC8), the N category in pancreatic ductal adenocarcinoma is classified as N0 (0), N1 (1–3), and N2 (≥ 4) based on the number of metastatic lymph nodes (LNs). This study aimed to validate this classification and analyze cutoff values of metastatic LN numbers.

Methods

Patients with pancreatic head ductal adenocarcinoma who underwent pancreaticoduodenectomy at our institution between 2005 and 2016 without preoperative therapy were retrospectively analyzed. The patients were staged by AJCC8, and prognostic analyses were performed. The best cutoff value for the metastatic LN number was determined by the minimum P value approach.

Results

In 228 of 309 patients, LN metastases were found (median number of examined LNs, 41). The median survival time (MST) was 56 months in the N0 group, 34 months in the N1 group, and 20 months in the N2 group (N0 vs N1: P = 0.023; N1 vs N2: P < 0.001). The best cutoff number of metastatic LNs was 4 for patients with LN metastases and 7 for patients with N2 disease. The MST for patients with four to six positive nodes (N2a) was significantly longer than for those with seven or more positive nodes (N2b) (24.0 vs 19.1 months: P = 0.012). For N2b patients, conventional adjuvant chemotherapy did not show survival benefits (P = 0.133), and overall survival did not differ significantly from that for patients with para-aortic LN metastasis (P = 0.562).

Conclusion

The N staging of AJCC8 was valid. Clinicians should regard N2b as similar to distant LN metastasis, and more intensive adjuvant therapy may be indicated for this group.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition): changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg. 2017;265:185–91. CrossRefPubMedPubMedCentral Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition): changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg. 2017;265:185–91. CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Murakami Y, Uemura K, Sudo T, et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg. 2010;211:196–204. CrossRefPubMed Murakami Y, Uemura K, Sudo T, et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg. 2010;211:196–204. CrossRefPubMed
3.
Zurück zum Zitat Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85. CrossRefPubMedPubMedCentral Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Malleo G, Maggino L, Capelli P, et al. Reappraisal of nodal staging and study of lymph node station involvement in pancreaticoduodenectomy with the Standard International Study Group of Pancreatic Surgery Definition of Lymphadenectomy for Cancer. J Am Coll Surg. 2015;221:367–79. Malleo G, Maggino L, Capelli P, et al. Reappraisal of nodal staging and study of lymph node station involvement in pancreaticoduodenectomy with the Standard International Study Group of Pancreatic Surgery Definition of Lymphadenectomy for Cancer. J Am Coll Surg. 2015;221:367–79.
5.
Zurück zum Zitat Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol. 2006;13:1189–200. CrossRefPubMed Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol. 2006;13:1189–200. CrossRefPubMed
6.
Zurück zum Zitat Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897–902. CrossRefPubMed Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897–902. CrossRefPubMed
7.
Zurück zum Zitat Ueda M, Endo I, Nakashima M, et al. Prognostic factors after resection of pancreatic cancer. World J Surg. 2009;33:104–10. CrossRefPubMed Ueda M, Endo I, Nakashima M, et al. Prognostic factors after resection of pancreatic cancer. World J Surg. 2009;33:104–10. CrossRefPubMed
8.
Zurück zum Zitat Akerberg D, Ansari D, Andersson R. Reevaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. World J Gastroenterol. 2016;22:6424–33. CrossRefPubMedPubMedCentral Akerberg D, Ansari D, Andersson R. Reevaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. World J Gastroenterol. 2016;22:6424–33. CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Kang MJ, Jang JY, Chang YR, Kwon W, Jung W, Kim SW. Revisiting the concept of lymph node metastases of pancreatic head cancer: number of metastatic lymph nodes and lymph node ratio according to N stage. Ann Surg Oncol. 2014;21:1545–51. CrossRefPubMed Kang MJ, Jang JY, Chang YR, Kwon W, Jung W, Kim SW. Revisiting the concept of lymph node metastases of pancreatic head cancer: number of metastatic lymph nodes and lymph node ratio according to N stage. Ann Surg Oncol. 2014;21:1545–51. CrossRefPubMed
10.
Zurück zum Zitat Shimada K, Nara S, Esaki M, Sakamoto Y, Kosuge T, Hiraoka N. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas. Pancreas. 2011;40:464–8. CrossRefPubMed Shimada K, Nara S, Esaki M, Sakamoto Y, Kosuge T, Hiraoka N. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas. Pancreas. 2011;40:464–8. CrossRefPubMed
11.
Zurück zum Zitat Shimada K, Sakamoto Y, Sano T, Kosuge T, Hiraoka N. Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. Pancreas. 2006;33:233–9. CrossRefPubMed Shimada K, Sakamoto Y, Sano T, Kosuge T, Hiraoka N. Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. Pancreas. 2006;33:233–9. CrossRefPubMed
12.
Zurück zum Zitat Basturk O, Saka B, Balci S, et al. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma has strong prognostic correlations: proposal for a revised n classification for TNM staging. Ann Surg Oncol. 2015;22(Suppl 3):S1187–95. CrossRefPubMed Basturk O, Saka B, Balci S, et al. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma has strong prognostic correlations: proposal for a revised n classification for TNM staging. Ann Surg Oncol. 2015;22(Suppl 3):S1187–95. CrossRefPubMed
13.
Zurück zum Zitat Bhatti I, Peacock O, Awan AK, Semeraro D, Larvin M, Hall RI. Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg. 2010;34:768–75. CrossRefPubMed Bhatti I, Peacock O, Awan AK, Semeraro D, Larvin M, Hall RI. Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg. 2010;34:768–75. CrossRefPubMed
14.
Zurück zum Zitat House MG, Gonen M, Jarnagin WR, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11:1549–55. CrossRefPubMed House MG, Gonen M, Jarnagin WR, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11:1549–55. CrossRefPubMed
15.
Zurück zum Zitat Paiella S, Malleo G, Maggino L, Bassi C, Salvia R, Butturini G. Pancreatectomy with para-aortic lymph node dissection for pancreatic head adenocarcinoma: pattern of nodal metastasis spread and analysis of prognostic factors. J Gastrointest Surg. 2015;19:1610–20. CrossRefPubMed Paiella S, Malleo G, Maggino L, Bassi C, Salvia R, Butturini G. Pancreatectomy with para-aortic lymph node dissection for pancreatic head adenocarcinoma: pattern of nodal metastasis spread and analysis of prognostic factors. J Gastrointest Surg. 2015;19:1610–20. CrossRefPubMed
16.
Zurück zum Zitat Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141:610–18. CrossRefPubMed Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141:610–18. CrossRefPubMed
17.
Zurück zum Zitat Showalter TN, Winter KA, Berger AC, et al. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys. 2011;81:1328–35. CrossRefPubMed Showalter TN, Winter KA, Berger AC, et al. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys. 2011;81:1328–35. CrossRefPubMed
18.
Zurück zum Zitat Tarantino I, Warschkow R, Hackert T, et al. Staging of pancreatic cancer based on the number of positive lymph nodes. Br J Surg. 2017;104:608–18. CrossRef Tarantino I, Warschkow R, Hackert T, et al. Staging of pancreatic cancer based on the number of positive lymph nodes. Br J Surg. 2017;104:608–18. CrossRef
19.
Zurück zum Zitat Elshaer M, Gravante G, Kosmin M, Riaz A, Al-Bahrani A. A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. Ann R Coll Surg Engl. 2017;99:101–6. CrossRefPubMedPubMedCentral Elshaer M, Gravante G, Kosmin M, Riaz A, Al-Bahrani A. A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. Ann R Coll Surg Engl. 2017;99:101–6. CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Strobel O, Hinz U, Gluth A, et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann Surg. 2015;261:961–9. CrossRefPubMed Strobel O, Hinz U, Gluth A, et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann Surg. 2015;261:961–9. CrossRefPubMed
21.
Zurück zum Zitat Amin MB. AJCC Cancer Staging Manual. 8th ed. Berlin: Springer; 2017. CrossRef Amin MB. AJCC Cancer Staging Manual. 8th ed. Berlin: Springer; 2017. CrossRef
22.
Zurück zum Zitat Japan_Pancreas_Society. Classification of Pancreatic Carcinoma. 4th English ed. Kanehara & Co., Ltd., Tokyo; 2017. Japan_Pancreas_Society. Classification of Pancreatic Carcinoma. 4th English ed. Kanehara & Co., Ltd., Tokyo; 2017.
23.
Zurück zum Zitat Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: a surveillance, epidemiology, and end results (SEER) analysis. Ann Surg Oncol. 2017;24:2023–30. CrossRefPubMed Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: a surveillance, epidemiology, and end results (SEER) analysis. Ann Surg Oncol. 2017;24:2023–30. CrossRefPubMed
24.
Zurück zum Zitat Kwon W, He J, Higuchi R, et al. Multinational validation of the American Joint Committee on Cancer 8th edition pancreatic cancer staging system in a pancreas head cancer cohort. J Hepatobiliary Pancreat Sci. 2018;25:418–27. CrossRefPubMed Kwon W, He J, Higuchi R, et al. Multinational validation of the American Joint Committee on Cancer 8th edition pancreatic cancer staging system in a pancreas head cancer cohort. J Hepatobiliary Pancreat Sci. 2018;25:418–27. CrossRefPubMed
25.
Zurück zum Zitat Song Y, Chen Z, Chen L, et al. A refined staging model for resectable pancreatic ductal adenocarcinoma incorporating examined lymph nodes, location of tumor and positive lymph nodes ratio. J Cancer. 2018;9:3507–14. CrossRefPubMedPubMedCentral Song Y, Chen Z, Chen L, et al. A refined staging model for resectable pancreatic ductal adenocarcinoma incorporating examined lymph nodes, location of tumor and positive lymph nodes ratio. J Cancer. 2018;9:3507–14. CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat van Roessel S, Kasumova GG, Verheij J, et al. International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer. JAMA Surg. 2018;153:e183617. CrossRefPubMed van Roessel S, Kasumova GG, Verheij J, et al. International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer. JAMA Surg. 2018;153:e183617. CrossRefPubMed
27.
Zurück zum Zitat NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 1. 2018. 2018. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 1. 2018. 2018.
28.
Zurück zum Zitat Shimada K, Sano T, Sakamoto Y, Kosuge T. Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma. Ann Surg Oncol. 2006;13:1569–78. CrossRefPubMed Shimada K, Sano T, Sakamoto Y, Kosuge T. Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma. Ann Surg Oncol. 2006;13:1569–78. CrossRefPubMed
29.
Zurück zum Zitat Sakamoto Y, Kokudo N, Matsuyama Y, et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer. 2016;122:61–70. CrossRefPubMed Sakamoto Y, Kokudo N, Matsuyama Y, et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer. 2016;122:61–70. CrossRefPubMed
30.
Zurück zum Zitat Valsangkar NP, Bush DM, Michaelson JS, et al. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17:257–66. CrossRefPubMed Valsangkar NP, Bush DM, Michaelson JS, et al. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17:257–66. CrossRefPubMed
31.
Zurück zum Zitat Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15:165–74. CrossRefPubMed Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15:165–74. CrossRefPubMed
32.
Zurück zum Zitat Liu ZQ, Xiao ZW, Luo GP, et al. Effect of the number of positive lymph nodes and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma. Hepatobiliary Pancreat Dis Int. 2014;13:634–41. CrossRefPubMed Liu ZQ, Xiao ZW, Luo GP, et al. Effect of the number of positive lymph nodes and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma. Hepatobiliary Pancreat Dis Int. 2014;13:634–41. CrossRefPubMed
33.
Zurück zum Zitat Huebner M, Kendrick M, Reid-Lombardo KM, et al. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:920–6. CrossRefPubMed Huebner M, Kendrick M, Reid-Lombardo KM, et al. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:920–6. CrossRefPubMed
34.
Zurück zum Zitat Kayahara M, Nagakawa T, Futagami F, Kitagawa H, Ohta T, Miyazaki I. Lymphatic flow and neural plexus invasion associated with carcinoma of the body and tail of the pancreas. Cancer. 1996;78:2485–91. CrossRefPubMed Kayahara M, Nagakawa T, Futagami F, Kitagawa H, Ohta T, Miyazaki I. Lymphatic flow and neural plexus invasion associated with carcinoma of the body and tail of the pancreas. Cancer. 1996;78:2485–91. CrossRefPubMed
35.
Zurück zum Zitat Kayahara M, Nagakawa T, Kobayashi H, et al. Lymphatic flow in carcinoma of the head of the pancreas. Cancer. 1992;70:2061–6. CrossRefPubMed Kayahara M, Nagakawa T, Kobayashi H, et al. Lymphatic flow in carcinoma of the head of the pancreas. Cancer. 1992;70:2061–6. CrossRefPubMed
36.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10. CrossRefPubMed Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10. CrossRefPubMed
37.
Zurück zum Zitat Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77. CrossRef Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77. CrossRef
38.
Zurück zum Zitat Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57. CrossRefPubMed Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57. CrossRefPubMed
39.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25. CrossRefPubMed Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25. CrossRefPubMed
40.
Zurück zum Zitat Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406. CrossRefPubMed Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406. CrossRefPubMed
41.
Zurück zum Zitat Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703. CrossRef Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703. CrossRef
42.
Zurück zum Zitat Gilabert M, Boher JM, Raoul JL, et al. Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: a retrospective analysis by the Association Francaise de Chirurgie. Med Baltim. 2017;96:e7214. CrossRef Gilabert M, Boher JM, Raoul JL, et al. Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: a retrospective analysis by the Association Francaise de Chirurgie. Med Baltim. 2017;96:e7214. CrossRef
43.
Zurück zum Zitat Eskander MF, de Geus SW, Kasumova GG, et al. Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer. Surgery. 2017;161:968–76. CrossRefPubMed Eskander MF, de Geus SW, Kasumova GG, et al. Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer. Surgery. 2017;161:968–76. CrossRefPubMed
44.
Zurück zum Zitat Ruess DA, Makowiec F, Chikhladze S, et al. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma. BMC Surg. 2015;15:123. CrossRefPubMedPubMedCentral Ruess DA, Makowiec F, Chikhladze S, et al. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma. BMC Surg. 2015;15:123. CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Zacharias T, Jaeck D, Oussoultzoglou E, Neuville A, Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg. 2007;11:350–6. CrossRefPubMed Zacharias T, Jaeck D, Oussoultzoglou E, Neuville A, Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg. 2007;11:350–6. CrossRefPubMed
Metadaten
Titel
A Single-Institution Validation Study of Lymph Node Staging By the AJCC 8th Edition for Patients with Pancreatic Head Cancer: A Proposal to Subdivide the N2 Category
verfasst von
MD Daisuke Asano
MD Satoshi Nara
MD Yoji Kishi
MD Minoru Esaki
MD Nobuyoshi Hiraoka
MD Minoru Tanabe
MD Kazuaki Shimada
Publikationsdatum
29.04.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07390-z

Weitere Artikel der Ausgabe 7/2019

Annals of Surgical Oncology 7/2019 Zur Ausgabe

Neu im Fachgebiet Chirurgie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.